The FDA Just Cleared the Dexcom G7 15-Day, the Longest-Lasting CGM

The FDA Just Cleared the Dexcom G7 15-Day, the Longest-Lasting CGM

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch - DexCom (NASDAQ:DXCM)

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute Relative Difference (MARD) of 8.0%, Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range. Also Read: Trump Tariffs Spare Drugmakers But Threaten Diabe…

Dexcom nets FDA clearance for 15-day CGM

The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.

Dexcom Surges After FDA Clears Its Next-Generation Diabetes Device

Dexcom stock surged Thursday after the Food and Drug Administration cleared its newest diabetes device for an extended 15-day period. The post Dexcom Surges After FDA Clears Its Next-Generation Diabetes Device appeared first on Investor's Business Daily.

FDA Clears New Dexcom G7 15 Day Continuous Glucose Monitoring System – RamaOnHealthcare

Pharmacists have positive impacts on health outcomes for diabetes and patients using CGM devices, including reductions in A1c.The FDA cleared the new

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.